Journal for Immunotherapy of Cancer

Article	Citations
Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma	247
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses	223
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047	206
Novel circulating microRNA signature for early detection and prognostication of checkpoint inhibitor-related pneumonitis	185
Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade	161
Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach	160
Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study	160
MAIT cells promote cancer progression and regulatory T cell accumulation in bladder tumor microenvironment	157
Constructing a pancancer ubiquitination regulatory network to determine tumor characteristics, immunotherapy response, and prognosis	150
Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis	150
Evaluation of immune checkpoint inhibitor efficacy for solid tumors with CD274 (PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwid	140
Inhibition of PNCK inflames tumor microenvironment and sensitizes head and neck squamous cell carcinoma to immune checkpoint inhibitors	137
Correction: Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockade	128
Author response to comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer	122
Response to "NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng	120
Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunothera	119
Correction: Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy	115
Commentary on oncolytic viruses: past, present, and future	114
Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models	114
Correction: Treg-selective IL-2 starvation synergizes with CD40 activation to sustain durable responses in lymphoma models	113
Zelig Eshhar (1941–2025): a tribute for a life for immunotherapy	111
Is immunotherapy safe and effective in patients with VEXAS syndrome?	108
Pancreatic cancer cell-intrinsic transglutaminase-2 promotes T cell suppression through microtubule-dependent secretion of immunosuppressive cytokines	106
Cbl-b inhibitor NX-1607 activates MAPK/ERK signaling pathway and enhances T-cell activation	106
Correction: influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors	103

Correction: PP4 inhibition sensitizes ovarian cancer to NK cell-mediated cytotoxicity via STAT1 activation and inflammatory signaling	103
Biomarkers for response to TIL therapy: a comprehensive review	102
HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype	99
Correction: Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer	99
Single-cell analysis reveals clonally expanded tumor-associated CD57 + CD8 T cells are enriched in the periphery of patients with metastatic urotheli	97
Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study	97
Differential phagocytosis induces diverse macrophage activation states in malignant gliomas	96
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap	95
Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells	93
Hybrid epithelial-mesenchymal status of lung cancer dictates metastatic success through differential interaction with NK cells	91
iRECIST and atypical patterns of response to immuno-oncology drugs	90
B7-H3 CAR-T cell therapy combined with irradiation is effective in targeting bulk and radiation-resistant chordoma cancer cells	88
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study	87
Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression	87
T-cell tolerant fraction as a predictor of immune-related adverse events	87
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy	86
Oncolytic adenovirus serotype 35 mediated tumor growth suppression via efficient activation of antitumor immunity	86
TIPE2 deletion improves the therapeutic potential of adoptively transferred NK cells	85
Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival	85
Intratumoral microbiota predicts the response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer	83
Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers	83
Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases	83
Lactylation-driven TNFR2 expression in regulatory T cells promotes the progression of malignant pleural effusion	82
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision	82
Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy	80
Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression	77
Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders	76
Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade	76
GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma	75
Macrophage-inherited exosome excise tumor immunosuppression to expedite immune-activated ferroptosis	75
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors	75
New insights into the role of IFN-α/β and TLR7/8/9 in cancer immunotherapy and systemic autoimmunity	75
Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer	73
Correction: Macrophage sensitivity to bexmarilimab-induced reprogramming is shaped by the tumor microenvironment	72
PI3Kδ/γ inhibitor BR101801 extrinsically potentiates effector CD8+ T cell-dependent antitumor immunity and abscopal effect after local irradiation	72
Cantharidin overcomes IL-2Rα signaling-mediated vorinostat resistance in cutaneous T-cell lymphoma through reactive oxygen species	72
Sulforaphane activates CD8+ T cells antitumor response through IL-12RB2/MMP3/FasL-induced MDSCs apoptosis’	72
Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch	71
Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination	71
A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma	71
Paclitaxel, interferons and functional reprogramming of tumor-associated macrophages in optimized chemo-immunotherapy	70
Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies	69
Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0	69
Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16	69
In memoriam: Soldano Ferrone, MD, PhD (1940–2023)	68
Cytoplasmic-delivery of polyinosine-polycytidylic acid inhibits pancreatic cancer progression increasing survival by activating Stat1-CCL2-mediated immunity	68
Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC	67
Oxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechalle	66
Correction: Antitumor strategies targeting macrophages: the importance of considering the differences in differentiation/polarization processes between human and mouse macrophages	66
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors	66

Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes	65
Accumulation of T-cell-suppressive PD-L1high extracellular vesicles is associated with GvHD and might impact GvL efficacy	65
Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation	65
Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies	64
TNFR2 blockade of regulatory T cells unleashes an antitumor immune response after hematopoietic stem-cell transplantation	64
Predictors of patients with advanced pancreatic cancer undergoing conversion surgery via chemoimmunotherapy with a multifunctional Wilms’ tumor 1 (WT1) peptide cocktail-pulsed dendritic cell vaccine	64
Correction: Tumor-associated macrophages induced spheroid formation by CCL18-ZEB1-M-CSF feedback loop to promote transcoelomic metastasis of ovarian cancer	64
Modulating lipid metabolism improves tumor immunotherapy	63
Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs	63
Pre-infusion risk factors predict severe infectious complications of CAR T-cell therapy in pediatric and adult patients with B-ALL	63
Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity	63
Tumor-secreted AGR2 induces dendritic cell dysfunction and impairs immunotherapy efficacy in LKB1-deficient cancer	62
Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironment	62
Targeting immunosuppressive macrophages by CSRP2-regulated CCL28 signaling sensitizes hepatocellular carcinoma to lenvatinib	62
Poor clinical outcomes and immunoevasive contexture in CD161+CD8+ T cells barren human pancreatic cancer	62
Stress-NRF2 response axis polarizes tumor macrophages and undermines immunotherapy	62
TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion	61
Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers	61
Irreversible electroporation synergizes with oncolytic virus enhances the infiltration of cytotoxic T lymphocytes in the tumor immune microenvironment: a leap from focal therapy to immunotherapy for p	61
Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia	61
Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications	61
Human blood cell transcriptomics unveils dynamic systemic immune modulation along colorectal cancer progression	61
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis	61
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial	60
Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models	60
SIGLEC11 promotes M2 macrophage polarization through AKT–mTOR signaling and facilitates the progression of gastric cancer	58
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy	58
Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer	58
Effect of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer: a prospective observation study	58
Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials	58
Vaccination generates functional progenitor tumor-specific CD8 T cells and long-term tumor control	58
TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma	58
Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells	58
PD-L1 gene amplification and focality: relationship with protein expression	58
Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses	57
CD33 KO -CD33-mesothelin Loop CAR design avoids fratricide and improves efficacy of iNK cells against acute myeloid leukemia	57
RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cells	57
Targeting KDM4C enhances CD8+ T cell mediated antitumor immunity by activating chemokine CXCL10 transcription in lung cancer	56
Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy	56
Targeting mesothelin-CD24 axis repolarizes tumor-associated macrophages to potentiate PD-1 blockade therapy in high-grade serous ovarian cancer	56
Novel post-translational modification learning signature reveals B4GALT2 as an immune exclusion regulator in lung adenocarcinoma	55
Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function	55
MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer	55
Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D	55
Apoptosis: a Janus bifrons in T-cell immunotherapy	54
PD-1 blockade employed at the time CD8+ T cells are activated enhances their antitumor efficacy	54
Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT	54
Targeting integrin α5 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition	53
Author response to Zhang et al	53
Peritumoral administration of immunomodulatory antibodies as a triple combination suppresses skin tumor growth without systemic toxicity	53
Multiomics identifies tumor-intrinsic SREBP1 driving immune exclusion in hepatocellular carcinoma	53
Rescuing natural killer cells from the cancer wilderness	53
Exploring molecular imaging to investigate immune checkpoint inhibitor-related toxicity	53
Correction: Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel	53
Correction: Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma	53
Guidelines for immunological analyses following focused ultrasound treatment	53
Gut microbiome-depleting antibiotic regimens are not tolerated by all mouse strains: learn from (our) bitter experience	52
Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex	52
Correction: Search for effective treatments in patients with advanced refractory melanoma continues: can novel intratumoral therapies deliver?	52
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)	52
Spatial immune remodeling of the liver metastases: discovering the path to antimetastatic therapy	52
Combination of a novel TCR Vβ chain-directed selective T cell activator with standard of care therapy for head and neck cancer improves antitumor responses and promotes regression of checkpoint-refrac	52
Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma	52
PLS-α-GalCer: a novel targeted glycolipid therapy for solid tumors	52
The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling	52
Novel oncolytic adenovirus-based PEPvIII vaccine displays a super antitumor effect in glioma models	52
Potentiation of cancer immunogenicity by targeting PARP	51
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma	51
Neoantigens as potential vaccines in hepatocellular carcinoma	51
Integrated single-cell transcriptome and TCR profiles of hepatocellular carcinoma highlight the convergence on interferon signaling during immunotherapy	51
Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report	51
Correction: Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody	51
Id-neoantigen vaccine induces therapeutic CD8+ T cells against multiple myeloma: H chain-loss escapees cause FLC MM	50
Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade	50
Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors	50
Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a ph	50
Anti-CTGF/PD-1 bispecific antibody Y126S restrains desmoplastic and immunosuppressive microenvironment in pancreatic cancer	50
Corticosteroid premedication on anti-tumor effect of immune checkpoint blockade in murine hepatocellular carcinoma models	50
Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG	50
Correction: Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers	50

Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer	50
Topical TLR7 agonist and radiotherapy in patients with metastatic breast cancer	50
Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy	49
Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization	49
Irreversible electroporation augments β-glucan induced trained innate immunity for the treatment of pancreatic ductal adenocarcinoma	48
Adoptive transfer of CMV-specific TCR-T cells for the treatment of CMV infection after haploidentical hematopoietic stem cell transplantation	48
Salmonella-mediated methionine deprivation drives immune activation and enhances immune checkpoint blockade therapy in melanoma	48
Correction: Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events	48
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors	48
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies	48
Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al	48
Immune-modulating effects on tumor-draining lymph nodes of neoadjuvant chemoradiotherapy combined with dual immunotherapy in patients with T3-4N0-2 NSCLC	48
TGFβ receptor inhibition unleashes interferon-β production by tumor-associated macrophages and enhances radiotherapy efficacy	47
Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation	47
Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy	47
Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)	47
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders	47
The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer	47
Network-based screening identifies sitagliptin as an antitumor drug targeting dendritic cells	46
Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma	46
Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses	46
Natural killer cells are required for the recruitment of CD8+ T cells and the efficacy of immune checkpoint blockade in melanoma brain metastases	45
Allele-specific HLA LOH in solid tumors: distinct patterns by tumor type and potential prognostic relevance	45
JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy	45
Adenovirus vaccine targeting kinases induces potent antitumor immunity in solid tumors	45
Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial	45
Reinforcing cancer immunotherapy with engineered porous hollow mycobacterium tuberculosis loaded with tumor neoantigens	45
Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity	45
TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8+ T cell and XCR1+ dendritic cell spatial co-localization	45
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome	45
HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity	45
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer	45
Blocking LIF and PD-L1 enhances the antitumor efficacy of SBRT in murine PDAC models	44
Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy	44
Serotonin receptor 5-HT2A as a potential target for HCC immunotherapy	44
Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockade	44
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors	44
Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial	44
Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer	44
Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study)	44
L-5-hydroxytryptophan promotes antitumor immunity by inhibiting PD-L1 inducible expression	44
Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysis	43
Letter to the editor: transfer learning radiomic model predicts intratumoral tertiary lymphoid structures in hepatocellular carcinoma: a multicenter study	43
Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C	43
Disruption of cell-intrinsic PCSK9 enhances the antitumor efficacy of CD8+ T cells	43
Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer	43
Correction: MRI techniques for immunotherapy monitoring	43
Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategies	43
Preclinical evaluation of two phylogenetically distant arenavirus vectors for the development of novel immunotherapeutic combination strategies for cancer treatment	43
CD56bright cytokine-induced memory-like NK cells and NK-cell engagers synergize against non-small cell lung cancer cancer-stem cells	43
Comment on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’	43
Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin	43
Correction: Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy	42
DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma	42
Selective BCL-2 inhibitor triggers STING-dependent antitumor immunity via inducing mtDNA release	42
Novel treatments for novel side effects: a case report and review of baricitinib use in the treatment of chronic inflammatory demyelinating polyneuropathy caused by immune checkpoint inhibitor use	42
Therapeutic inhibition of USP7 promotes antitumor immune responses	42
Spatial TCR clonality and clonal expansion in the in situ microenvironment of non-small cell lung cancer	42
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas	42
Constructing the cure: engineering the next wave of antibody and cellular immune therapies	42
Assessment and predictive ability of the absolute neutrophil count in peripheral blood for in vivo CAR T cells expansion and CRS	41
Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma	41
Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes	41
Polymorphonuclear myeloid-derived suppressor cells and phosphatidylinositol-3 kinase gamma are critical to tobacco-mimicking oral carcinogenesis in mice	41
No detrimental association between antibiotic use and immune checkpoint inhibitor therapy: an observational cohort study comparing patients with ICI-treated and TKI-treated melanoma and NSCLC	41
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive	41
Body mass index and type 2 diabetes mellitus as metabolic determinants of immune checkpoint inhibitors response in melanoma	41
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab	41
Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry	41
Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins	41
Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression	41
Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?	41
Hyperglycemia induces an immunosuppressive microenvironment in colorectal cancer liver metastases by recruiting peripheral blood monocytes through the CCL3-CCR1 axis	40
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma	40
Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial	40
Inhibition of osteosarcoma lung metastases by β-glucan and CD40 agonist is mediated by activation of macrophages and NK cells	40
Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase	40
In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade	40
Paired single-B-cell transcriptomics and receptor sequencing reveal activation states and clonal signatures that characterize B cells in acute myeloid leukemia	40
Specific inhibitor to KRASG12C induces tumor-specific immunity and synergizes with oncolytic virus for enhanced cancer immunotherapy	40
Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses	39
TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma	39
Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response: insights from a prospective study	39
Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy	39
Vaccines for immunoprevention of DNA mismatch repair deficient cancers	39
NK cells link immune-checkpoint blockade immunotherapy and response in melanoma brain metastases	39
Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression	39
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia	38
Uncoupled biological and chronological aging of neutrophils in cancer promotes tumor progression	38
Dynamic modulation of claudin18.2 expression and remodeling of the tumor microenvironment in gastric cancer during chemo-immunotherapy	38
Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer	38
CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors	38
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types	38
Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis	38
ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers	37